Artelo Biosciences to Present Novel Scientific Insights for ART26.12 at the 4th ACE Drug Discovery Summit on April 3, 2025
Artelo Biosciences (NASDAQ: ARTL) has announced that Lead Medicinal Chemist Myles Osborn will present at the 4th ACE Drug Discovery Summit in London on April 3, 2025. The presentation, scheduled for 12:30pm BST, will focus on analyzing multiple datasets regarding Fatty Acid Binding Protein 5 (FABP5) inhibition across various disease models.
The presentation, titled 'Comparative Multi-Omics to Interrogate Consensus Mechanisms of FABP5i Across Diverse Indications,' will explore how FABP5 inhibition affects cellular communication pathways. Research has shown promising activity in treating neuropathic pain, osteoarthritis, cancer, and cancer bone pain.
The company's lead FABP5 inhibitor, ART26.12, is currently in Phase 1 Single Ascending Dose study with healthy volunteers, with data expected in Q2 2025.
Artelo Biosciences (NASDAQ: ARTL) ha annunciato che il Capo Chimico Medicinale Myles Osborn presenterà al 4° ACE Drug Discovery Summit a Londra il 3 aprile 2025. La presentazione, programmata per le 12:30 BST, si concentrerà sull'analisi di più set di dati riguardanti l'inibizione della Proteina di Legame degli Acidi Grassi 5 (FABP5) attraverso vari modelli di malattia.
La presentazione, intitolata 'Multi-Omica Comparativa per Indagare i Meccanismi di Consenso dell'Inibizione di FABP5 in Diverse Indicazioni,' esplorerà come l'inibizione di FABP5 influisca sui percorsi di comunicazione cellulare. La ricerca ha mostrato un'attività promettente nel trattamento di dolore neuropatico, osteoartrite, cancro e dolore osseo da cancro.
L'inibitore principale di FABP5 dell'azienda, ART26.12, è attualmente in uno studio di Fase 1 con dose ascendente singola su volontari sani, con dati attesi nel secondo trimestre del 2025.
Artelo Biosciences (NASDAQ: ARTL) ha anunciado que el Químico Medicinal Principal Myles Osborn presentará en la 4ª Cumbre de Descubrimiento de Medicamentos ACE en Londres el 3 de abril de 2025. La presentación, programada para las 12:30 BST, se centrará en el análisis de múltiples conjuntos de datos sobre la inhibición de la Proteína de Unión de Ácidos Grasos 5 (FABP5) en diversos modelos de enfermedad.
La presentación, titulada 'Multi-Ómicas Comparativas para Investigar Mecanismos de Consenso de FABP5i en Diversas Indicaciones,' explorará cómo la inhibición de FABP5 afecta las vías de comunicación celular. La investigación ha mostrado una actividad prometedora en el tratamiento de dolor neuropático, osteoartritis, cáncer y dolor óseo por cáncer.
El principal inhibidor de FABP5 de la compañía, ART26.12, está actualmente en un estudio de Fase 1 de Dosis Ascendente Única con voluntarios sanos, con datos esperados para el segundo trimestre de 2025.
아르텔로 바이오사이언스(나스닥: ARTL)는 수석 약리 화학자인 마일스 오스본이 2025년 4월 3일 런던에서 열리는 제4회 ACE 약물 발견 정상 회담에서 발표할 것이라고 발표했습니다. 발표는 BST 기준 오후 12시 30분에 예정되어 있으며, 다양한 질병 모델에서 지방산 결합 단백질 5(FABP5) 억제와 관련된 여러 데이터 세트를 분석하는 데 초점을 맞출 것입니다.
'다양한 적응증의 FABP5i의 합의 메커니즘을 조사하기 위한 비교 다중 오믹스'라는 제목의 발표는 FABP5 억제가 세포 통신 경로에 미치는 영향을 탐구할 것입니다. 연구 결과는 신경병증 통증, 골관절염, 암 및 암성 골통 치료에 유망한 활성을 보여주었습니다.
회사의 주요 FABP5 억제제인 ART26.12는 현재 건강한 자원봉사자를 대상으로 한 1상 단일 용량 상승 연구 중이며, 2025년 2분기에 데이터가 예상됩니다.
Artelo Biosciences (NASDAQ: ARTL) a annoncé que le chimiste médicinal principal Myles Osborn présentera au 4ème Sommet sur la Découverte de Médicaments ACE à Londres le 3 avril 2025. La présentation, prévue à 12h30 BST, se concentrera sur l'analyse de plusieurs ensembles de données concernant l'inhibition de la Protéine de Liaison des Acides Gras 5 (FABP5) à travers divers modèles de maladies.
La présentation, intitulée 'Multi-Omique Comparative pour Interroger les Mécanismes de Consensus de l'Inhibition de FABP5 à Travers Diverses Indications,' explorera comment l'inhibition de FABP5 affecte les voies de communication cellulaire. Les recherches ont montré une activité prometteuse dans le traitement de la douleur neuropathique, de l'arthrose, du cancer et de la douleur osseuse liée au cancer.
L'inhibiteur principal de FABP5 de l'entreprise, ART26.12, est actuellement en phase 1 d'une étude de dose unique ascendante avec des volontaires en bonne santé, avec des données attendues au deuxième trimestre 2025.
Artelo Biosciences (NASDAQ: ARTL) hat angekündigt, dass der leitende Arzneimittelchemiker Myles Osborn am 4. ACE Drug Discovery Summit am 3. April 2025 in London präsentieren wird. Die Präsentation, die für 12:30 Uhr BST geplant ist, wird sich auf die Analyse mehrerer Datensätze zur Hemmung des Fettsäure-bindenden Proteins 5 (FABP5) in verschiedenen Krankheitsmodellen konzentrieren.
Die Präsentation mit dem Titel 'Vergleichende Multi-Omics zur Untersuchung von Konsensmechanismen der FABP5i über verschiedene Indikationen' wird untersuchen, wie die FABP5-Hemmung die zellulären Kommunikationswege beeinflusst. Die Forschung hat vielversprechende Aktivitäten bei der Behandlung von neuropathischen Schmerzen, Osteoarthritis, Krebs und Knochenschmerzen durch Krebs gezeigt.
Der führende FABP5-Hemmer des Unternehmens, ART26.12, befindet sich derzeit in einer Phase-1-Studie mit einmalig steigenden Dosen an gesunden Freiwilligen, mit Daten, die im 2. Quartal 2025 erwartet werden.
- None.
- None.
SOLANA BEACH, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced that Myles Osborn, Lead Medicinal Chemist at Artelo Biosciences, will be presenting at 12:30pm BST on April 3, 2025 during the 4th ACE Drug Discovery Summit being held at The Insurance Hall, London, UK.
In the course of the presentation, titled “Comparative Multi-Omics to Interrogate Consensus Mechanisms of FABP5i Across Diverse Indications,” Mr. Osborn will discuss an analysis of multiple datasets across different disease models related to deeper understanding of the impact of downstream biology of Fatty Acid Binding Protein 5 (FABP5) inhibition and share new insights by which this novel target may impact therapeutic developments across a wide array of potential indications.
FABP5 plays a key role within cellular communication pathways and inhibition of the target has demonstrated activity in models of neuropathic pain, osteoarthritis, cancer, and cancer bone pain. A Phase 1 Single Ascending Dose study in healthy volunteers with ART26.12, Artelo’s lead FABP5 inhibitor, is nearing completion with data expected in Q2 2025.
About ART26.12
ART26.12, Artelo’s lead Fatty Acid Binding Protein 5 (FABP5) inhibitor, is being developed as a novel, peripherally acting, non-opioid, non-steroidal analgesic. Cleared by the FDA for a first-in-human study in the US, data from the first Phase 1 trial with ART26.12 is anticipated in Q2 2025. The initial clinical development planned is for chemotherapy-induced peripheral neuropathy (CIPN). Fatty Acid Binding Proteins (FABPs) are a family of intracellular proteins that chaperone lipids important to normal cellular function. FABP is overexpressed and associated with abnormal lipid signaling in a number of pathologies. In addition to ART26.12 in CIPN, Artelo’s extensive library of small molecule inhibitors of FABPs has shown therapeutic promise for the treatment of certain cancers, neuropathic and nociceptive pain, psoriasis, and anxiety disorders.
About Artelo Biosciences
Artelo Biosciences, Inc. is a clinical stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways including the endocannabinoid system. Artelo is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, pain, neuropathy, and inflammation. Led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts, the company applies leading edge scientific, regulatory, and commercial discipline to develop high-impact therapies. More information is available at www.artelobio.com and Twitter: @ArteloBio.
About ACE Drug Discovery Summit
The 4th ACE Drug Discovery Summit, 2025 provides a platform for scientists, researchers, and decision makers from all over the world debate on the latest scientific advances, trends, current challenges and futuristic advancements in Drug Discovery. The two-day conference is designed to maximize collaborations and innovation discussions among pharma and technology experts with presentations and interactive sessions between professionals from industry and academia. The Summit features cutting edge scientific advancements in the areas of drug discovery, AI, screening automation, high content imaging, disease modelling, cell and gene therapy. To register for the ACE Drug Discovery Summit, please visit: https://acxpo.com/4th-ace-drug-discovery-summit/
Forward Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission, including our ability to raise additional capital in the future. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by applicable securities laws.
Investor Relations Contact:
Crescendo Communications, LLC
Tel: 212-671-1020
Email: ARTL@crescendo-ir.com 
FAQ
When will Artelo Biosciences (ARTL) release Phase 1 data for ART26.12?
What medical conditions could ART26.12 potentially treat?
What is the focus of ARTL's presentation at the 4th ACE Drug Discovery Summit?
What is the current development stage of ARTL's ART26.12?
Where and when will ARTL present their latest research findings?
